Transplantation in Waldenstrom's macroglobulinemia—the French experience

Tournilhac, Olivier; Leblond, Véronique; Tabrizi, Reza; Gressin, Rémy; Sénécal, Delphine; Milpied, Noël; Cazin, Bruno; Diviné, Marine; Dreyfus, Brigitte; Cahn, Jean Yves; Pignon, B.; Desablens, B; Perrier, Jean‐François; Bay, Jacques‐Olivier; Travade, Philippe

doi:10.1053/sonc.2003.50048

Cited by 61 publications

(39 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The largest single center study is the French report of 19 patients in whom a 1-year treatment-related mortality of 6% and PFS of 45% was observed. 15 Although the length of follow-up was relatively short (range from 0.8 to 2.8 years), these results suggested that further exploration of auto-HCT for relapsed WM was warranted. Anagnostopoulos et al, 16 on behalf of the Center for International Blood and Marrow Transplant Research, also reported a series of 36 patients of whom 10 were recipients of high-dose chemotherapy followed by peripheral blood auto-HCT.…”

Section: Auto-hct For Wmmentioning

confidence: 97%

“…In the French experience, at a median follow-up of 1.5 years, 6 of 10 patients with advanced WM remained disease-free, whereas 4 died from transplant complications. 15 A report from Canada demonstrated that 4 of 5 patients remained free of disease at a median follow-up of 32 months and demonstrated progressive, delayed decline of IgM over 6 months, which is suggestive of an active GVL effect. 21 A retrospective WM analysis reported to the Center for International Blood and Marrow Transplant Research included 26 allo-HCT recipients.…”

Section: Allo-hct For Wmmentioning

confidence: 99%

“…[12][13][14][15][16][17][18][19][20] A total of 24 previously published cases, reviewed by Anagnostopoulos et al 12 included heavily pretreated patients treated with a variety of conditioning regimens, including melphalan 200 mg/m 2 , thiotepa/BU/CY, or CY with TBI. These regimens were relatively well tolerated with low treatment-related mortality, manageable non-hematological toxicities and promising response rates.…”

Section: Auto-hct For Wmmentioning

confidence: 99%

See 2 more Smart Citations

Hematopoietic cell transplantation for Waldenström macroglobulinemia

Bachanová

Burns

2011

Bone Marrow Transplant

View full text Add to dashboard Cite

Waldenstro¨m macroglobulinemia (WM) is a distinct indolent B-cell lymphoproliferative malignancy characterized by IgM paraproteinemia. Although the disease is sensitive to chemo-immunotherapy, it remains incurable and affected patients have a median survival of 5-10 years. Risk stratification in newly diagnosed patients should start with a prognostic evaluation based on the International Prognostic Scoring System for WM (IPSSWM) to identify those patients in whom particularly poor survival with chemotherapy is expected and in whom alternative treatment strategies, such as hematopoietic cell transplantation (HCT), should be considered. High-dose chemotherapy followed by autologous HCT (auto-HCT) results in disease-free survival of 45-65% at 5 years, but is unlikely to be curative. Chemosensitive disease at the time of auto-HCT is the most important prognostic factor for response rate and overall survival. Allogeneic donor HCT may offer a unique immunemediated GVL effect with a plateau in relapse rates and potential for extended disease-free survival. The risk of allogeneic HCT complications is justified in HCT-eligible patients whose expected survival is o5 years. Here, we present the advances in non-transplant strategies and the therapeutic role of transplant, and suggest a treatment algorithm for selecting a HCT strategy while adhering to current evidence supporting autologous and allogeneic donor HCT for WM.

show abstract

Section: Auto-hct For Wmmentioning

confidence: 97%

Section: Allo-hct For Wmmentioning

confidence: 99%

Section: Auto-hct For Wmmentioning

confidence: 99%

See 1 more Smart Citation

Hematopoietic cell transplantation for Waldenström macroglobulinemia

Bachanová

Burns

2011

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…43 The first report of the French experience with transplants to treat Waldenströ m was published in 2003. 44 Waldenströ m patients underwent 19 autologous transplants. The median time between diagnosis and transplant was 36 months.…”

Section: Autologous Stem Cell Transplantmentioning

confidence: 99%

“…44 All the transplant patients received myeloablative conditioning. Four of the patients died at 3, 11, 12 and 18 months; three patients died of microangiopathic hemolytic anemia.…”

Section: Allogeneic Stem Cell Transplantmentioning

confidence: 99%

Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique

Gertz

Reeder

Kyle

et al. 2011

Bone Marrow Transplant

View full text Add to dashboard Cite

Waldenströ m macroglobulinemia is a highly chemosensitive lymphoplasmacytic lymphoma with response rates of 90% to firstline chemotherapy. The fraction of patients undergoing stem cell transplant for this disorder appears to be lower than that of patients with multiple myeloma. The indolent nature and favorable genetic profile should make Waldenströ m an ideal disorder for autologous stem cell transplant, with high response rates that are durable. We review the literature on autologous and allogeneic transplants for Waldenströ m macroglobulinemia and conclude that autologous transplant is effective and underutilized in the management of this disorder. Allogeneic transplant should be considered investigational and used only in the context of a clinical trial or when other chemotherapeutic options have been exhausted.

show abstract

Aetiology and Management of Non‐Hodgkin's Lymphoma

Avivi¹,

Goldstone²

2005

Postgraduate Haematology

View full text Add to dashboard Cite

Transplantation in Waldenstrom's macroglobulinemia—the French experience

Cited by 61 publications

References 17 publications

Hematopoietic cell transplantation for Waldenström macroglobulinemia

Hematopoietic cell transplantation for Waldenström macroglobulinemia

Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique

Aetiology and Management of Non‐Hodgkin's Lymphoma

Contact Info

Product

Resources

About